Funding
The IMPROV study was funded by the UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404). KT is funded through an CSL Centenary Fellowship. RJC is funded by an Australian National Health and Medical Research (NHMRC) Emerging Leader Investigator Grant (1194702), JAS by a NHMRC Leadership Investigator Grant (1196068) and RNP by a NHMRC Leadership Investigator Grant (2008501). The study funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. All authors had full access to the data in the study and had final responsibility for the decision to submit for publication.